Publication date: Sep 20, 2023
Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates of infection and vaccination in communities. This study evaluated infection rates based on total anti-nucleocapsid immunoglobulin (N) and/or infection history. We determined the seroprevalence of anti-receptor binding domain (RBD) antibodies across age groups. A cross-sectional study was conducted in Chonburi province, Thailand, between October 2022 and January 2023. Participants included newborns to adults aged up to 80 years. All serum samples were tested for anti-N total Ig and anti-RBD IgG. The interviewer-administered questionnaires queried information on infection history and vaccination records. Of 1459 participants enrolled from the Chonburi population, ~ 72. 4% were infected. The number of infections was higher in children aged 60 years. Our findings will help predict the exact number of infections and the seroprevalence of SARS-CoV-2 in the Thai population. Furthermore, this information is essential for public health decision-making and the development of vaccination strategies.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Aged60years | Anti |
| Epidemiology | Antibodies |
| January | Cov |
| Serum | Cross |
| Thailand | Igg |
| Infection | |
| Nucleocapsid | |
| October | |
| Rbd | |
| Sars | |
| Sectional | |
| Seroprevalence | |
| Thailand | |
| Total | |
| Vaccination |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infection |
| disease | VO | vaccination |
| disease | IDO | history |
| disease | VO | population |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | SARS CoV 2 infection |
| disease | VO | vaccinated |
| disease | MESH | Communicable Diseases |
| drug | DRUGBANK | Fenamole |
| disease | VO | vaccine |
| disease | IDO | production |
| disease | VO | inactivated vaccine |
| disease | IDO | blood |
| disease | VO | dose |
| disease | VO | titer |
| disease | MESH | morbidities |
| disease | VO | report |
| disease | IDO | immune response |
| disease | VO | vaccine dose |
| disease | VO | time |
| disease | IDO | country |
| disease | VO | unvaccinated |
| disease | MESH | vaccine preventable diseases |
| disease | VO | protocol |
| disease | MESH | malignancy |
| disease | MESH | chronic diseases |
| disease | MESH | congenital defects |
| drug | DRUGBANK | Indoleacetic acid |
| disease | IDO | assay |
| disease | VO | milliliter |
| pathway | REACTOME | Immune System |
| disease | MESH | reinfection |
| disease | MESH | breakthrough infection |
| disease | VO | Comirnaty |
| disease | VO | CoronaVac |
| disease | VO | USA |
| drug | DRUGBANK | Zalcitabine |
| disease | VO | volume |
| drug | DRUGBANK | Etoperidone |
| drug | DRUGBANK | Trestolone |